(Q37044226)

17 August 2017

1 reference

title

Effect of ADRB2 polymorphisms on response to longacting beta2-agonist therapy: a pharmacogenetic analysis of two randomised studies (English)

1 reference

17 August 2017

1

Eugene R Bleecker

1 reference

17 August 2017

2

Dirkje S Postma

1 reference

17 August 2017

Rachael M Lawrance

3

1 reference

17 August 2017

Deborah A Meyers

series ordinal

4

1 reference

17 August 2017

Helen J Ambrose

series ordinal

5

1 reference

17 August 2017

Mitch Goldman

series ordinal

6

1 reference

17 August 2017

language of work or name

English

0 references

publication date

1 December 2007

1 reference

17 August 2017

1 reference

17 August 2017

volume

370

1 reference

17 August 2017

issue

9605

1 reference

17 August 2017

page(s)

2118-2125

1 reference

Budesonide/formoterol combination therapy as both maintenance and reliever medication in asthma

17 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961906-0

7 January 2021

Inhaled corticosteroid reduction and elimination in patients with persistent asthma receiving salmeterol: a randomized controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961906-0

7 January 2021

Effect of inhaled formoterol and budesonide on exacerbations of asthma. Formoterol and Corticosteroids Establishing Therapy (FACET) International Study Group.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961906-0

7 January 2021

Meta-analysis: effect of long-acting beta-agonists on severe asthma exacerbations and asthma-related deaths

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961906-0

7 January 2021

Pharmacological management to reduce exacerbations in adults with asthma: a systematic review and meta-analysis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961906-0

7 January 2021

Therapeutic responses in asthma and COPD. Bronchodilators

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961906-0

7 January 2021

Mutations in the gene encoding for the beta 2-adrenergic receptor in normal and asthmatic subjects

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961906-0

7 January 2021

Sequence, haplotype, and association analysis of ADRbeta2 in a multiethnic asthma case-control study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961906-0

7 January 2021

Meta-analysis of the association of beta2-adrenergic receptor polymorphisms with asthma phenotypes

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961906-0

7 January 2021

Amino-terminal polymorphisms of the human beta 2-adrenergic receptor impart distinct agonist-promoted regulatory properties.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961906-0

7 January 2021

The effect of polymorphisms of the beta(2)-adrenergic receptor on the response to regular use of albuterol in asthma

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961906-0

7 January 2021

Use of regularly scheduled albuterol treatment in asthma: genotype-stratified, randomised, placebo-controlled cross-over trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961906-0

7 January 2021

Asthma exacerbations during long term beta agonist use: influence of beta(2) adrenoceptor polymorphism

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961906-0

7 January 2021

beta-Adrenergic receptor polymorphisms and response to salmeterol

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961906-0

7 January 2021

Salmeterol response is not affected by beta2-adrenergic receptor genotype in subjects with persistent asthma

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961906-0

7 January 2021

The Salmeterol Multicenter Asthma Research Trial: a comparison of usual pharmacotherapy for asthma or usual pharmacotherapy plus salmeterol

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961906-0

7 January 2021

Safety of long-acting beta-agonists--an urgent need to clear the air.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961906-0

7 January 2021

Effect of budesonide/formoterol maintenance and reliever therapy on asthma exacerbations.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961906-0

7 January 2021

Standards for the diagnosis and care of patients with chronic obstructive pulmonary disease (COPD) and asthma. This official statement of the American Thoracic Society was adopted by the ATS Board of Directors, November 1986

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961906-0

7 January 2021

Detection of genotyping errors by Hardy-Weinberg equilibrium testing.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961906-0

7 January 2021

A note on exact tests of Hardy-Weinberg equilibrium

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961906-0

7 January 2021

Bronchodilator response in relation to beta2-adrenoceptor haplotype in patients with asthma

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961906-0

7 January 2021

Asthma variability in patients previously treated with beta2-agonists alone

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961906-0

7 January 2021

Heterogeneity of therapeutic responses in asthma

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961906-0

7 January 2021

Complex promoter and coding region beta 2-adrenergic receptor haplotypes alter receptor expression and predict in vivo responsiveness

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961906-0

7 January 2021

10.1016/S0140-6736(07)61906-0

Identifiers

DOI

1 reference

17 August 2017

1 reference